That is why the protocol structure matters as much as the peptide itself, and why the decision about dose, frequency, and cycle length belongs in a clinical consultation rather than a research forum
Sitagliptin and linagliptin are the strongest DPP-4 inhibitors with the greatest potential to improve bone metabolism, as demonstrated in preclinical and clinical studies [107]
doi: 10.1210/jc.2002-020696 169 RavussinESmithSR
As a result, the long-term GI safety of these agents continues to be actively investigated
It is unremarkable, and it is what you should expect by default from two agents acting on related pathways
GLP-1 therapy isnt forever for everyone, but it is most effective when paired with consistent support and sustainable habits